Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.

ABSTRACT:

Importance

Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration. Evidence on the treatment effect of tenecteplase 0.25 mg/kg in Chinese patients with acute ischemic stroke (AIS) is limited.

Objective

To establish the noninferiority of tenecteplase to alteplase in patients with AIS within 4.5 hours of symptom onset.

Design, setting, and participants

The ORIGINAL study was a multicenter, active-controlled, parallel-group, randomized, open-label, blinded end point, noninferiority trial conducted between July 14, 2021, and July 14, 2023. Participants were recruited from 55 neurology clinics and stroke centers in China and were eligible if they had AIS with a National Institutes of

SUBMITTER: Meng X 

PROVIDER: S-EPMC11393753 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature